The P-III (OCARINA II) trial assesses the safety, PK profile as well as radiological & clinical effects of Ocrevus (920mg, SC) vs Ocrevus (IV) to treat patients (n=236) with relapsing MS (RMS) or primary progressive MS (PPMS)
The updated, long-term data demonstrated a near-complete relapse activity suppression (97% had no relapse) & reduced MRI at 48wks. as well as an ARR of 0.04 with patients showing no T1 Gd+ & new/enlarging T2 lesions. Exploratory patient reported outcomes (n=52) suggested high satisfaction (92.3%) & convenience (90.1%) with Ocrevus SC injection
Moreover, the company’s submissions have been accepted by the EMA & the US FDA with the decision anticipated in mid-2024 and Sep 2024, respectively
Ref: Roche | Image: Roche
Related News:- Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
